Today, the shares of Zur Rose Group AG (“Zur Rose”) were traded for the first time under the “International Reporting Standard” of SIX Swiss Exchange, opening at CHF 151.00. This corresponds to a total market capitalization of around CHF 904 million.
The issued share capital of Zur Rose now comprises 5,984,539 registered shares with a nominal value of CHF 5.75 per share. Zur Rose issued 1,430,000 new registered shares in the offering, thereby raising CHF 200 million in gross proceeds (before exercise of the over-allotment option). In addition to the newly issued shares, 136,052 registered shares were sold by existing shareholders in the base offering. At the opening price of CHF 151.00, the placement volume corresponds to an amount of around CHF 236 million (before exercise of the over-allotment option). Furthermore, existing shareholders have granted the underwriters an over-allotment option of up to 234,908 additional registered shares.
Operating under the “Zur Rose” and “DocMorris” brands, the Swiss-based Zur Rose Group is Europe’s leading pure play online pharmacy and one of Switzerland’s foremost wholesale suppliers to medical practitioners. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process.
Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany).